ThermoGenesis has declared that it has signed a license and distribution contract with BioParadox for its Res-Q 60 BMC (Res-Q) System offering BioParadox the sole rights to utilize the Res-Q system for automating the PRP production from peripheral blood after the instigation and conclusion of clinical trials by BioParadox for claiming and continuing the exclusive rights.
The Res-Q is a diagnostic device developed for the cell concentrates production. Its present design facilitates the processing of stem cells from the aspirate of the bone marrow. PRP production from peripheral blood can be achieved by slight alteration of the Res-Q system. Thermogenesis has submitted a form 510(k) with FDA and is looking forward for its approval for authorizing the company to deploy the Res-Q technology for the production of PRP form peripheral blood.
J. Melville Engle, CEO of ThermoGenesis has stated their partnership with BioParadox denotes a milestone in their research work to develop innovative applications for their privately owned Res-Q technology. He added that they had proven the Res-Q technology in their labs proving that their technology is ideal for PRP production and they are looking forward to submitting the follow-up 510(k) file with FDA in another couple of weeks. He expressed that the PRP segment will continue to develop and this current agreement has placed both the companies in the center of the promising field.